References
- Baribeau S, Chaudhry P, Parent S, et al (2014). Resveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell lines. PLoS One, 9, 86987. https://doi.org/10.1371/journal.pone.0086987
- D'Amico AV, Cote K, Loffredo M, et al (2002). Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol, 20, 4567-73. https://doi.org/10.1200/JCO.2002.03.061
- Du LB, Li HZ, Wang XH, et al (2014). Analysis of cancer incidence in Zhejiang cancer registry in China during 2000 to 2009. Asian Pac J Cancer Prev, 15, 5839-43. https://doi.org/10.7314/APJCP.2014.15.14.5839
- Florea AM, Büsselberg D (2011). Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel), 3, 1351-71. https://doi.org/10.3390/cancers3011351
- Gavert N, Ben-Ze'ev A (2008). Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Molecular Medicine, 14, 199-209. https://doi.org/10.1016/j.molmed.2008.03.004
- Han R-F, Ji X, Dong X-G, et al (2014). An epigenetic mechanism underlying doxorubicin induced EMT in the human BGC-823 gastric cancer cell. Asian Pac J Cancer Prev, 15, 4271-4. https://doi.org/10.7314/APJCP.2014.15.10.4271
-
Han R, Xiong J, Xiao R, et al (2013). Activation of
$\beta$ -catenin signaling is critical for doxorubicin-induced epithelialmesenchymal transition in BGC-823 gastric cancer cell line. Tumor Biol, 34, 277-84. https://doi.org/10.1007/s13277-012-0548-3 - Hansen MB, Nielsen SE, Berg K (1989). Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunological Methods, 119, 203-10. https://doi.org/10.1016/0022-1759(89)90397-9
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA: Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Jung K-W, Won Y-J, Kong H-J, et al (2013). Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treatment, 45, 1-14. https://doi.org/10.4143/crt.2013.45.1.1
- Kalluri R, Weinberg RA (2009). The basics of epithelialmesenchymal transition. J Clin Invest, 119, 1420-8. https://doi.org/10.1172/JCI39104
- Kelland L (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer, 7, 573-84. https://doi.org/10.1038/nrc2167
- Lang BJ, Nguyen L, Nguyen HC, et al (2012). Heat stress induces epithelial plasticity and cell migration independent of heat shock factor 1. Cell Stress Chaperones, 17, 765-78. https://doi.org/10.1007/s12192-012-0349-z
- Latifi A, Abubaker K, Castrechini N, et al (2011). Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem, 112, 2850-64. https://doi.org/10.1002/jcb.23199
- Ruijter J, Ramakers C, Hoogaars W, et al (2009). Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res, 37, 45 https://doi.org/10.1093/nar/gkp045
- Siddik ZH (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 22, 7265-79. https://doi.org/10.1038/sj.onc.1206933
- Siegel R, Ma J, Zou Z, et al (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29. https://doi.org/10.3322/caac.21208
- Strober W (2001). Trypan blue exclusion test of cell viability. Current protoc immunol, Appendix 3:Appendix 3B.
- Yue PY, Leung EP, Mak NK, et al (2010). A simplified method for quantifying cell migration/wound healing in 96-well plates. J Biomol Screen, 15, 427-33. https://doi.org/10.1177/1087057110361772
Cited by
- The relationship between platinum drug resistance and epithelial–mesenchymal transition vol.91, pp.2, 2017, https://doi.org/10.1007/s00204-016-1912-7